Q3 FY26 · Ended Jun 30, 2026 · View SEC filing
The spread widened, not just the volume
Revenue rose 5.1%, but OneOncology's practice services and larger LIFO credits lifted gross profit far faster, the filing says.
For investorsWhat has to hold for the margin step to last
For foundersMoving next to your customer's customer
Cencora pays manufacturers after 59.7 days, longer than it holds stock and waits for customers, so growth tends to release cash.
Operating income rose 29.1%, but pre-tax income only 11.2%, as new deal debt and lower other income took the difference.
International brings 9.1% of revenue but 14.8% of operating income: abroad, Cencora keeps more of each dollar it sells.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Cencora from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
